The deal between Aurobindo Pharma and Spectrum Pharma for seven oncology injectables involves an upfront payment of $160 million, plus up to $140 million on achieving sales-based and regulatory targetsfrom homepage
The deal between Aurobindo Pharma and Spectrum Pharma for seven oncology injectables involves an upfront payment of $160 million, plus up to $140 million on achieving sales-based and regulatory targetsfrom homepage
Post a Comment